PRESS RELEASES

Press releases

2023

May 9 2023
Grifols delivers strong first quarter financials with 23% revenue growth and an Adjusted EBITDA margin above guidance of 21%

May 8 2023
Grifols realigns management structure to accelerate company performance and simplify its corporate governance

February 28 2023
Grifols delivers strong 2022 performance and is positioned for sustainable future growth

February 21 2023
Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation

February 15 2023
Grifols announces comprehensive operational improvement plan including EUR 400 million annualized cost savings initiative

January 31 2023
Grifols included in Bloomberg Gender-Equality Index for the third consecutive year for its leadership in equality, diversity and inclusion

2022

December 12 2022
Grifols recognized as one of the world’s most sustainable companies by Dow Jones Sustainability Index for third consecutive year

November 8 2022
Grifols’ Biopharma delivers robust 34% operational growth in Q3, driving revenues to EUR 4,351m in the first nine months of 2022

November 4 2022
Grifols invites investors to listen to webcast of November 8 Conference Call with Analysts

October 3 2022
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

September 26 2022
Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility

September 23 2022
Grifols’ credit rating reaffirmed by Moody’s and Fitch based on strong fundamentals and improving performance

September 7 2022
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

July 28 2022
Grifols’ business momentum delivers EUR 2,810 million in revenues and EUR 618 million in EBITDA as plasma collections accelerate

June 10 2022
Grifols highlights an increase in plasma and underscores innovation and sustainability as key growth pillars in its AGM

May 6 2022
Business Update 1Q 2022: Grifols accelerating plasma recovery while enhancing performance

April 25 2022
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation

February 28 2022
Grifols demonstrates resilient performance despite a challenging backdrop while recovery in plasma collection gains momentum

February 24 2022
Grifols signs global collaboration agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis

January 26 2022
Grifols maintains its standing in the Bloomberg Gender-Equality Index for its commitment to equality

January 26 2022
Grifols achieves a high level of acceptance of its PTO to Biotest and advances on its strategic transaction

January 11 2022
Grifols announces the expiration of the Asset sale Offer

2021

December 14 2021
Grifols moves forward with its divestment plan by agreeing to sell VCN Biosciences

December 13 2021
Grifols announces the commencement of an Asset sale Offer

November 17 2021
Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion

November 15 2021
Grifols is included on the Dow Jones Sustainability World Index

November 11 2021
Grifols advances on the execution of its strategic plan

October 26 2021
Grifols earns approval for the voluntary public tender offer of Biotest and advances its strategy to increase the availability of plasma-derived medicines

October 13 2021
Grifols increases access to plasma-derived therapies as part of its commitment to donors and patients

October 6 2021
Grifols divests its hemostasis technology business for USD 25 million

October 5 2021
Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest

September 27 2021
Grifols earns its first Fitch corporate rating with a BB- and stable outlook

September 17 2021
Grifols announces its investment in Biotest

August 16 2021
Grifols advances on its strategic investment from GIC with 90% of consents from its notes holders and lenders

July 30 2021
Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan

July 29 2021
The Bioscience Division grows 5.1% in the second quarter and raises first-half revenues to EUR 2,537 million

July 20 2021
Grifols endorses its commitment to a responsible business model and support of the 2030 Agenda for Sustainable Development by formally joining the United Nations Global Compact

June 30 2021
Grifols announces a strategic investment from GIC of USD 1 billion

May 21 2021
Grifols reaffirms its commitment to sustainability and innovation in its AGM and celebrates its 15th anniversary of being listed

May 4 2021
Grifols maintains its revenues and operational levels while enhancing its innovation strategy and securing its plasma supply

April 7 2021
Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S.

April 2 2021
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

March 9 2021
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

March 4 2021
Grifols publishes its 2020 Integrated Annual Report as part of its commitment to sustainability

March 1 2021
Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation

February 26 2021
Grifols increases its revenues to 5,340 M€ and continues to demonstrate its resilience and commitment to sustainable growth

January 27 2021
Grifols is included in the Bloomberg Gender-Equality Index for its commitment to gender equality

2020

December 16 2020
Grifols creates a Sustainability Committee to strengthen its long-term sustainable growth model

December 9 2020
Grifols is included on Euronext Vigeo indices and recognized once again as one of the world's most sustainable companies

November 24 2020
Strategic alliance between Grifols and the Egyptian government to boost plasma-derived medicines self-sufficiency in the Middle East and Africa

November 16 2020
The Dow Jones Sustainability Index recognizes Grifols as one of the world’s most sustainable companies

November 9 2020
Grifols consolidates its Hospital Division as a reference in innovative solutions with the acquisition of the 49% stake in MedKeeper

November 5 2020
Grifols continues delivering solid revenue and earnings growth driven by the Bioscience and Diagnostic Divisions

October 9 2020
Grifols underlines the importance of plasma in its Annual General Shareholders’ Meeting

October 1 2020
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

September 14 2020
Grifols more committed than ever to its values and long-term vision six months into the pandemic

September 7 2020
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

July 30 2020
Grifols revenues grow 10.5% to EUR 2,677 million driven by the Bioscience Division

July 28 2020
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials

July 27 2020
Results of Grifols’ AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association

July 23 2020
Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products

July 20 2020
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million

July 9 2020
Grifols starts commercializing TAVLESSE^® in Europe, diversifying its medicines portfolio

June 11 2020
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19

May 7 2020
Grifols reinforces its liquidity position to EUR 1,700 million

April 21 2020
Grifols maintains its operational levels and continues to reinforce its commitment to society

April 21 2020
Grifols continues to reinforce its commitment to all stakeholders as a response to COVID-19

March 27 2020
Grifols and Shanghai RAAS close their strategic alliance in China

March 25 2020
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19

March 18 2020
Grifols reinforces its commitment to all stakeholders as a response to the COVID-19 outbreak

February 27 2020
Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million

February 18 2020
Grifols and the Public Investment Fund of Saudi Arabia to boost plasma medicines self-supply in the region

January 16 2020
Grifols to launch TAVLESSE^® in Europe and Turkey to continue reinforcing its commercial strategy and commitment to patients

2019

December 12 2019
Grifols launches XEMBIFY^® 20% subcutaneous immunoglobulin, a new Primary Immunodeficiency treatment

December 6 2019
Grifols presents its latest Alzheimer’s clinical trial data

December 4 2019
Grifols introduces its first plasma protein-based biosurgery product

November 15 2019
Grifols completes its debt-refinancing in record time and with strong acceptance for EUR 5,800 million

November 13 2019
Grifols and Shanghai RAAS obtain authorization for their strategic alliance in China

October 29 2019
Grifols increases its revenues by 14.5% to EUR 3,738 million

July 31 2019
Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan

July 16 2019
Grifols presents additional encouraging Alzheimer’s trial results at AAIC

July 4 2019
Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies

May 24 2019
Grifols reinforces its long-term and sustainable growth strategy with EUR 1,400 million in capital investments in 2018-2022

May 23 2019
Grifols publishes its 2018 Corporate Responsibility Report as part of its commitment to transparency

May 7 2019
Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance

March 29 2019
Grifols presents new data to support the effectiveness of its clinical trial to treat Alzheimer's

March 7 2019
Grifols enters a strategic alliance with Shanghai RAAS to boost growth of its plasma-derived products and diagnostic solutions in China

February 28 2019
Grifols reports EUR 4,487 million in revenues, with 9.2% operating growth and EUR 597 million in net profit

January 23 2019
Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals

2018

November 5 2018
Bioscience Division revenues drive operational growth to 9.6% in the third quarter and boost net profits to Euros 468 million

October 27 2018
Grifols AMBAR results demonstrate a significant reduction in the progression of moderate Alzheimer's Disease

September 7 2018
Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives

August 1 2018
Grifols expands its plasma collection network by acquiring 24 Biotest centers in the United States

July 27 2018
Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7%

July 16 2018
Grifols has been included in the FTSE4Good Index

May 25 2018
Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends

May 23 2018
Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency

May 10 2018
Grifols reaches an agreement with Boya Bio-Pharmaceutical to open plasma collection centers in China

March 20 2018
Grifols expands and diversifies its plasma collection network with the acquisition of 35 donation centers in Germany from Aton

February 28 2018
Grifols revenues exceed EUR 4,300 million and reported profit reaches EUR 663 million

January 26 2018
Grifols reinforces its Hospital Division by acquiring a 51% stake in the U.S. technology firm MedKeeper for USD 98 million

2017

December 5 2017
Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives

November 17 2017
FDA approval of genetic test for alpha-1 deficiency and EMA approval of fibrin sealant

September 22 2017
FDA approves Grifols Prolastin^®-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency

July 28 2017
Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions

July 5 2017
Grifols opens new lines of research with the acquisition of a 44% stake in GigaGen for USD 35 million

May 26 2017
Grifols allocates Euros 218 million to dividends, with a compound annual growth rate of 16% over the last 4 years

May 3 2017
Bioscience Division sales increase 15% to drive Grifols' revenue growth by 11% to Euros 1,062 million

February 28 2017
Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division

February 6 2017
Grifols refinances debt for USD 6.3 billion, reducing the margin to 200 bps and extending its maturities

January 31 2017
Grifols closes the acquisition of Hologic's share of NAT donor screening unit for USD 1,850 million

2016

December 14 2016
Grifols agrees to acquire Hologic's share of NAT donor screening unit for USD 1,850 million

November 8 2016
Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million

July 28 2016
Sales of the Bioscience Division grow by +7.0%, increasing Grifols' revenues by +2.7% to EUR 1,952 million

May 27 2016
Grifols allocates EUR 213 million to dividends and maintains pay-out at 40% of consolidated net profit

May 5 2016
Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the Bioscience Division

March 8 2016
Grifols will invest USD 360M to expand its manufacturing capacities for plasma-derived therapies

February 29 2016
Grifols' revenues grow by 17.3% to Euros 3,935 million, and net profit grows by 13.2% reaching Euros 532 million

January 26 2016
Grifols invests in the project led by AlbaJuna Therapeutics, a spin-off from IrsiCaixa, to fund the development of therapeutic antibodies against HIV

2015

December 14 2015
Grifols makes public its succession plan: the envisaged generational handover reiterates the commitment of the founding family to the company

November 6 2015
The intermediate results from the Grifols AMBAR study support its continuation

November 4 2015
Grifols’ net profit rises by 18.5% to exceed Euros 400 million, and revenue rises by 17.8% to Euros 2,872 million

October 28 2015
Grifols agrees long term loan with the European Investment Bank

October 22 2015
Grifols official opening of the Bioscience Division new worldwide operations facility in Ireland

July 30 2015
Grifols' net profit rises by 16.3% to Euros 261.5 million and revenues by 18% exceeding Euros 1,900 million

May 29 2015
Grifols allocates €188 million to dividends and maintains payout at 40% of consolidated net profit

May 29 2015
Grifols non-profit Ebola initiative (in Spanish version)

May 7 2015
Grifols' net profit up by +6.2% to 128.5 million euros and sales grow by 13.8% in the first quarter of 2015

March 4 2015
Grifols to make a major equity investment in Alkahest

February 26 2015
Grifols achieves a record net profit of 470.3 million euros with growth of 36.1% in 2014

January 2 2015
Grifols receives FDA approval for its new purification plant to produce Gamunex in Los Angeles

2014

November 4 2014
Grifols' net profit increases by 26.9% to 339 million euros in the nine months to September 2014

September 19 2014
Grifols acquires 50% of the share capital of Kiro Robotics for 21 million euros

July 31 2014
Grifols' net profit rises by 23% to 224.8 million euros in the First Half of 2014

May 30 2014
Grifols sets payout at 40% of consolidated net profit

May 6 2014
Grifols' net profit rises by 32.9% to 121.0 million euros in the First Quarter of 2014

May 3 2014
Grifols opens new plasma fractionation plant in Spain

March 28 2014
Japanese Red Cross selects Grifols as partner for nucleic acid screening of nation's blood supply

March 17 2014
Grifols average cost of debt below 3.5% after a reduction of more than 2 points

February 27 2014
Grifols' sales rose by 4.6% to Euros 2,741.7 million

2013

December 17 2013
Shareholders endorse Grifols' Growth strategy

November 11 2013
Grifols to acquire a Novartis diagnostics business unit for US$1,675 million

November 5 2013
Grifols' net profit rose by 35.3% to 267 million euros in the nine months period to September 2013

July 31 2013
Grifols' net profit rose by 36.9% to 183 million euros in the first half of 2013

July 15 2013
Moody's upgrades Grifols' credit ratings with stable outlook

May 24 2013
Grifols holds its Ordinary General Shareholders' Meeting

May 14 2013
Grifols officially inaugurates new immunoglobulin plant in the United States

May 2 2013
Grifols' Net Profit Rises by 34.8% to 91 million Euros in the First Quarter of 2013

March 4 2013
Grifols acquires 60% of the capital of biotechnology firm Progenika Biopharma

February 28 2013
Grifols' sales increased by 46% to 2.620 million euros in 2012

2012

December 4 2012
Grifols' shareholders approve bonus share issue as a remuneration formula

October 31 2012
Grifols' sales increased by 14.4% to 1,959.5 million euros in the first nine months of 2012

September 19 2012
Grifols' Alzheimer research strategy addresses the degenerative disease from a global perspective

September 19 2012
Grifols' Comprehensive Research Strategy in Alzheimer

September 17 2012
Grifols agrees to purchase three plasma donation centers in the United States from Canada's Cangene

August 1 2012
Standard & Poor's Upgrades Grifols' Credit Rating

July 31 2012
Grifols' sales increase by 15.2% to 1,316.7 million euros in the 1H 2012

July 9 2012
Moody's upgrades Grifols' Credit Rating and changes Outlook to Positive

May 24 2012
Grifols holds its Ordinary General Shareholders' Meeting

April 24 2012
Grifols' turnover increased by 17.7% to 666.7 million euros in the first quarter of 2012

March 15 2012
Grifols has acquired 51% of the capital of Araclon Biotech to ensure the viability of the purchased company projects

February 28 2012
Grifols' sales increase by 7,7% in constant currency terms in 2011 to 2,300 millon euros

2011

December 7 2011
Victor Grifols selected as "Business Leader of the Year 2011" by the Spain - U.S. Chamber of Commerce

December 2 2011
Grifols' shareholders approve bonus share issue as a remuneration formula

November 11 2011
Grifols' sales grow 8% in constant currency terms to 1,712.6 million euros in the 9 months period to September 30, 2011

October 28 2011
Grifols calls Extraordinary General Shareholders' Meeting

July 28 2011
Grifols sales in the first half of 2011 increase 30.2%

May 24 2011
Grifols holds its General Ordinary Shareholders Meeting

May 5 2011
Grifols´ sales grow 10.0% to 261.4 million Euros in the first quarter of 2011

May 5 2011
Grifols´ sales grow 10.0% to261.4 million Euros in the first quarter of 2011

May 2 2011
Grifols and Talecris Biotherapeutics announce the signing of a Consent Agreement with FTC Staff

February 24 2011
Grifols' turnover increased by 8.5% in 2010 to 990.7 million euros

February 22 2011
Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US

February 18 2011
Grifols starts construction of a new plasma fractionation plant in Barcelona

February 18 2011
Grifols starts construction of a new plasma fractionation plant in Parets del Vallès

January 25 2011
Grifols' shareholders approve the issue of nonvoting shares required to complete the acquisition of Talecris

January 13 2011
Grifols closes USD 1.1 billion bond issue(This release will not be distributed in the United States of America, Canada, Australia or Japan)

January 13 2011
Grifols closes 1.1 billion dollar bond issue

2010

December 15 2010
Grifols obtains EMA license to market its IVIG, Flebogamma® DIF, at 10% concentration

December 15 2010
Grifols obtains EMA license to market its Flebogamma® DIF at 10% concentration

November 24 2010
Grifols signs term loan agreements related to Talecris acquisition for USD 3.4 billion

November 23 2010
Grifols announces US launch of Flebogamma DIF 10% IVIG

November 22 2010
Grifols Announces US Launch of Flebogamma® 10% DIF IVIG

November 4 2010
Grifols´ turnover increased by 7.1% in the first nine months of 2010 to 738.8 MM

November 4 2010
Grifols' turnover increased by 7.1% in the first nine months of 2010 to 738.8MM Euros

September 28 2010
Grifols continues investing to boost its Diagnostic division

September 27 2010
Grifols continues investing to boost its Diagnostics division

September 15 2010
Grifols expects to close for an amount of USD1.5B the first tranche of the syndicated Financing to acquire Talecris

September 2 2010
Grifols obtains FDA license in the US market for its IVIG Flebogamma

July 29 2010
At 487.8 million Euros, Grifols sales in the first half of 2010 increase 3.7%

July 29 2010
Grifols sales in the first half of 2010 increase 3.7% up to 487.8 million Euros

July 20 2010
Grifols obtains its first crédit rating from Standard & Poor's and Moody's

June 24 2010
Progenika Biopharma grants Grifols Worldwide distribution of its Bloodchip

June 24 2010
Progenika Biopharma grants Grifols World-wide distribution of its Bloodchip

June 21 2010
Grifols holds its Annual General Meeting

June 7 2010
Grifols to acquire Talecris Biotherapeutics creating a world leading provider of life-saving plasma protein therapies

June 2 2010
Grifols initiates clinical investigation of a new treatment protocol for Alzheimer's disease

May 20 2010
Grifols agrees to acquire intellectual property for treatment of post-polio syndrome from pharmalink AB

May 20 2010
Grifols agreement with Pharmalink to acquire the intellectual property for the treatment of Post-Polio Syndrome (PPS)

April 28 2010
Sales of plasma products have grown by 8.2% at constant currency, reaching 184.6 million euros in the first quarter of 2010 and driving the group´s turnover

April 28 2010
Sales of plasma products have grown by 8.2% at constant currency, reaching 184.6 million euros inthe first quarter of 2010 and driving the group¿s turnover

February 25 2010
Grifols' net profit increased by 21.6% in 2009 to 148 MM euros

2009

December 23 2009
Grifols obtains FDA approval for a new in filling area in its Albumin plant in LA

December 23 2009
Grifols obtains FDA approval for new sterile albumin filling plant in Los Angeles

December 16 2009
Grifols and financial institutions unanimously agree the novation of the syndicated facility

December 9 2009
Grifols builds a new solutions factory in Murcia

November 4 2009
Grifols reports a 14.9% increase in revenue in the first nine months of 2009 to 689.6 MM euros

October 26 2009
Spanish minister of Industry, Tourism and Trade visits Grifols' facilities in LA.

October 16 2009
Grifols to break ground on a new testing laboratory in San Marcos, Texas (US).

October 7 2009
Grifols completes its USD600 million corporate bond issue in the US

September 21 2009
Grifols publishes interim results of its clinical trial on Alzheimer's disease

July 29 2009
Grifols' net profit rose 31.4% in the first half of 2009 to 81.7 MM euros

July 29 2009
Grifols obtains USD 10.7 million loan to fund the purchase of 4 plasma centres in the United States

July 27 2009
Grifols' net profit rose 31.4% in the first half of 2009 to 81.7 MM euros

June 30 2009
Health Robotics and Grifols sign a collaboration agreement

June 30 2009
Grifols gets a minority stake in Cardio3 BioSciences

June 30 2009
Health Robotics and Grifols sign a collaboration agreement

June 21 2009
Grifols holds its Annual General Meeting

June 11 2009
Grifols promotes European research into liver cirrhosis

May 28 2009
The shares of Grifols will be traded in the United States through ADRs

May 26 2009
Cerus and Grifols Extend INTERCEPT Blood System Distribution to Italy

April 28 2009
Grifols' net profit rose 33.8 % in the first quarter of 2009 to 41.6 million euros

March 3 2009
Grifols acquires control over a Swiss and Australian group through a €25 million investment

March 3 2009
GRIFOLS acquires control over a Swiss and Australian group through a €25 million investment

February 26 2009
Grifols' net profit advanced 38.7% in 2008 to 121.7 million euros.

January 28 2009
Grifols Academy of Plasmapheresis opens in US

January 19 2009
Grifols gets a minority stake in Cardio3 BioSciences

2008

October 30 2008
Grifols boosts nine-month net profit by 43% to 92.8 million euros

October 14 2008
Grifols obtains marketing licence for its Intravenous Immunoglobulin Flebogamma

October 14 2008
Flebogamma® DIF receives licensing in Australia

August 27 2008
Grifols´ net profit rose 36.8% in the first half of 2008 to 62.2 million euros

August 27 2008
Grifols' net profit rose 36.8% in the first half of 2008 to 62.2 million euros

July 29 2008
Grifols obtains USD 10.7 million loan to fund the purchase of 4 plasma centres in the United States

June 13 2008
Grifols holds its Ordinary General Meeting of Shareholders

June 10 2008
Grifols signs an agreement with Gambro Renal Products (GRP) for MARS

May 26 2008
Grifols obtains syndicated financing for 350 million euros

May 14 2008
Grifols' net profit rose 33% in the first quarter of 2008 to 31.1 million euros

May 10 2008
Grifols signs an agreement with Gambro Renal Products (GRP) for MARS

May 7 2008
Grifols obtains FDA licence for new filling area at its plasma products plant in the USA

May 6 2008
Grifols obtains FDA licence for new filling area at its plasma products plant in the USA

April 23 2008
Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement

April 15 2008
Grifols signs a new distribution agreement with CDEX for Spain, Portugal and Italy

April 15 2008
Grifols signs a new distribution agreement with CDEX

March 12 2008
Grifols signs agreement with Stough Development Corp. to open 10 new plasma collection centers in the United States

March 12 2008
Grifols signs agreement with Stough Development Corporation to open 10 new plasma collection Centers in the United States

February 28 2008
Net profits for Grifols increased 93.4% in 2007 to reach 87.8 million euros

January 17 2008
Grifols acquires Novartis' former industrial complex 0f 31,000 square meters in Parets del Valles, Barcelona

January 17 2008
Grifols' R&D is qualified as "Excellent" in the 2007 edition of the Plan Profarma. (spanish version)

2007

December 11 2007
The TAC incorporates Grifols into the Ibex-35

November 22 2007
Grifols successfully concludes the transition to its new intravenous immunoglobulin, Flebogamma DIF

November 8 2007
Grifols increased its business turnover by 8.7% in the first nine months of thr year to 524.5 million euros

October 30 2007
Grifols to announce Capital Investment Plan for 400 million over the next five years

October 22 2007
Grifols and Laboratorios Divasa sign a strategic cooperation agreement

October 1 2007
Grifols and the Department for Professional, Artistic and Specialized Higher Education sign an agreement to promote higher education in the Vallès Occidental area.

August 29 2007
Grifols increases its income by 11.4% to 358 million euros in the first six months of the year

August 28 2007
Grifols obtains EMEA authorization for sale of new generation IVIG in Europe

July 23 2007
Grifols S.A. and Cerus Corporation agree to commercialize the INTERCEPT Blood System in Spain and Portugal

June 20 2007
Grifols holds its Ordinary General Meeting of Shareholders

May 10 2007
Grifols' turnover reaches 182 million euros in the first quarter of 2007

May 4 2007
Grifols will manage 4 new plasma centers in the United States

April 18 2007
Grifols looks into acquiring Diesse, an Italian company specialized in in vitro diagnostics

March 22 2007
Grifols R&D is qualified as excellent in the Profarma Plan 2006 meeting

February 26 2007
Grifols reports a 23.8 increase in sales in 2006

2006

December 27 2006
Grifols licensed by the FDA to market a new generation of IGIV in the United States

November 6 2006
Grifols reports a 23.7% increase in sales in the first nine months of 2006

October 12 2006
Grifols launches PatientCare Program to address insurance lapses for hemophilia community

July 25 2006
Grifols' Diagnostic division launches new in vitro diagnosis line

June 19 2006
Grifols signs an agreement with Kardex Remstar for Latin America

May 16 2006
Grifols sets offer price at €4.4 per share. The offering is 10 times oversubscribed

April 5 2006
Grifols holds its General Shareholders Meeting

March 2 2006
Grifols closes out 2005 with a 15% increase in turnover

March 1 2006
Grifols acquires 15 additional plasma collection centers through acquisition of PlasmaCare